B

BioPlus Co Ltd
KOSDAQ:099430

Watchlist Manager
BioPlus Co Ltd
KOSDAQ:099430
Watchlist
Price: 7 700 KRW 1.99% Market Closed
Market Cap: 433.5B KRW
Have any thoughts about
BioPlus Co Ltd?
Write Note

BioPlus Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BioPlus Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
B
BioPlus Co Ltd
KOSDAQ:099430
Cash & Cash Equivalents
â‚©46B
CAGR 3-Years
42%
CAGR 5-Years
68%
CAGR 10-Years
N/A
SD Biosensor Inc
KRX:137310
Cash & Cash Equivalents
â‚©482.4B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
HLB Inc
KOSDAQ:028300
Cash & Cash Equivalents
â‚©89.7B
CAGR 3-Years
-20%
CAGR 5-Years
11%
CAGR 10-Years
45%
T
T&L Co Ltd
KOSDAQ:340570
Cash & Cash Equivalents
â‚©19.3B
CAGR 3-Years
-18%
CAGR 5-Years
47%
CAGR 10-Years
N/A
H
Humasis Co Ltd
KOSDAQ:205470
Cash & Cash Equivalents
â‚©9.7B
CAGR 3-Years
-49%
CAGR 5-Years
18%
CAGR 10-Years
N/A
I
Interojo Co Ltd
KOSDAQ:119610
Cash & Cash Equivalents
â‚©10.4B
CAGR 3-Years
12%
CAGR 5-Years
6%
CAGR 10-Years
13%
No Stocks Found

BioPlus Co Ltd
Glance View

Market Cap
433.5B KRW
Industry
Health Care

BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.

Intrinsic Value
15 791.58 KRW
Undervaluation 51%
Intrinsic Value
Price
B

See Also

What is BioPlus Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
46B KRW

Based on the financial report for Dec 31, 2023, BioPlus Co Ltd's Cash & Cash Equivalents amounts to 46B KRW.

What is BioPlus Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
68%

Over the last year, the Cash & Cash Equivalents growth was 151%. The average annual Cash & Cash Equivalents growth rates for BioPlus Co Ltd have been 42% over the past three years , 68% over the past five years .

Back to Top